Print

Astex Pharmaceuticals (ASTX) Release: Cancer Research Technology and Cancer Research UK Cambridge Research Institute Initiate AT13148 Clinical Trial to Treat Several Cancer Types  
1/17/2013 9:16:44 AM

DUBLIN, Calif., Jan. 16, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that collaborators Cancer Research UK and its commercial arm Cancer Research Technology (CRT) are launching a trial of an experimental drug shown to simultaneously block many enzymes that control cancer cell growth and death. The 'master-switch' experimental drug, owned by Astex Pharmaceuticals, is being studied in a range of cancer types.
//-->